AXT, Inc. (AXTI) SEC Filings & Earnings Calls
EquiReason read 21 AXT, Inc. SEC filings in the last 12 months. Latest: 10-Q on 2026-08-13 — AXT reports continued impact from US tariffs and China export controls, with North America revenue dropping to 2% of total, and withdrawal of STAR Market IPO triggering $49M redemp.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 3.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
13 Aug 202610-QAXT reports continued impact from US tariffs and China export controls, with North America revenue dropping to 2% of total, and withdrawal of STAR Market IPO triggering $49M redemption rights.open
Figures in the filing · each found in the filing text
| North America revenue as % of total · FY2025 | 2.0% | |
| Gross margin · Q3-2025 | 22.3% | |
| Tariffs paid · FY2025 | $300000.00 | -70% y/y |
| Dividends from PRC subsidiaries · H1-2026 | $2M |
Risks flagged
Export permit uncertainty for InP to US
“InP export permits represent the most significant challenge we currently face. ... we still cannot predict when a permit application will be reviewed and approved.” · word for word
IPO withdrawal triggers $49M redemption liability
“each Investor has the right, but not the obligation, to require the Company to redeem its investment, and the Company has the right, but not the obligation, to redeem each Investor’s investment, in each case for a price equal to the original amount invested, without interest or any other return.” · word for word
US tariff escalation to 70%
“On March 4, 2025, the United States further increased the tariff on imports of many products, including our wafer substrates, to 70%.” · word for word
China regulatory intervention risk
“The PRC central government may intervene in or influence our PRC operations at any time and the rules and regulations in China can change quickly with little advance notice.” · word for word
30 Jul 20268-K · 2.02Revenue $48M (+164% y/y); GAAP gross margin 44.9; Non-GAAP gross margin 45earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $48M | +164% y/y |
| GAAP gross margin · Q2-2026 | 44.9% | |
| Non-GAAP gross margin · Q2-2026 | 45.0% | |
| GAAP net income · Q2-2026 | $11M | |
| Non-GAAP net income · Q2-2026 | $12M | |
| GAAP diluted EPS · Q2-2026 | $0.17 | |
| Non-GAAP diluted EPS · Q2-2026 | $0.19 |
Risks flagged
Dependence on data center optical connectivity demand; potential cyclicality
“Strong customer demand for data center optical connectivity... we are working closely with our direct customers as well as major end customers” · word for word
China manufacturing exposure; geopolitical and supply chain risks
“Manufacturing facilities in three separate locations in China... partial ownership in more than ten companies in China” · word for word
29 Jul 20268-K · 1.01AXT entered a 6-year Capacity Reservation Agreement with Lumentum for InP wafer substrates, with $87M in deposits and minimum annual purchase commitments, signaling strong demand visibility.open
Figures in the filing · each found in the filing text
| Deposit · Q3-2026 | $44M | |
| Deposit · FY2028 | $44M |
Risks flagged
Customer concentration risk with Lumentum as a single large customer.
“Agreement with Lumentum Operations LLC for a significant portion of capacity.”
Execution risk in meeting minimum annual capacity commitments; failure could lead to deposit refunds.
“Failure to deliver minimum annual Product Capacity constitutes material breach and may require refund of deposits.”
22 Jul 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
No material risk; routine board expansion.
“Standard director election with no controversy.”
8 Jul 20268-K · 2.04Triggered an off-balance-sheet financial obligationopen
Risks flagged
No content available to assess risk.
“Empty body excerpt.”
2 Jul 20268-K · 1.01AXT subsidiary entered a 3-year Master Development and Supply Agreement with Coherent Corp for 6-inch InP wafer substrates, including a $22.29M prepayment and capacity commitment, indicating strong demand and customer investment.open
Figures in the filing · each found in the filing text
| Prepayment · 2026-06-26 | $22M |
Risks flagged
Customer concentration risk with Coherent; prepayment refundable if capacity not met.
“Prepayment refundable if AXT fails to meet Capacity Commitment for more than 6 months.”
Geopolitical risk from China-based manufacturing facility.
“Manufacturing capacity increase at Beijing, China facility.”
17 Jun 20268-K · 1.01AXT subsidiary Tongmei entered a long-term supply agreement with Casela for InP wafer substrates, with a committed purchase of ~$25.4M in 2027, including a 50% prepayment and 80% minimum purchase clause.open
Figures in the filing · each found in the filing text
| Committed purchase price · InP wafer substrates · FY2027 | $25M |
Risks flagged
Customer concentration risk; Casela is a single counterparty for a material contract.
“Agreement with Nanjing Casela Technologies Corporation, Ltd.” · word for word
14 May 202610-QNorth America Revenue as % of Total 2; Gross Margin 22.3; Tariffs Paid $300,000.00 (-70% y/y)open
Figures in the filing · each found in the filing text
| North America Revenue as % of Total · North America · FY2025 | 2.0% | |
| Gross Margin · Q3-2025 | 22.3% | |
| Tariffs Paid · FY2025 | $300000.00 | -70% y/y |
| Dividends Paid to AXT by PRC Subsidiaries · Q1-2026 | $0.00 | |
| Equity in Income of Unconsolidated Joint Ventures · FY2025 | $800000.00 | -77% y/y |
| Substrate Revenue as % of Total · Substrate · FY2025 | 67.0% | |
| Raw Materials Revenue as % of Total · Raw Materials · FY2025 | 33.0% |
Risks flagged
Export Permit Uncertainty
“InP export permits represent the most significant challenge we currently face.” · word for word
U.S.-China Trade Escalation
“The trade and political tensions between China and the U.S. remain high and controls on exports and tariffs are changing and fluid.” · word for word
Revenue Concentration in China
“All of our wafer substrates are manufactured in China.” · word for word
Gross Margin Volatility
“Our gross margin has fluctuated historically and may decline due to several factors.” · word for word
Tongmei IPO Failure
“The proposed Tongmei IPO on the STAR Market in China could fail to be completed.” · word for word
30 Apr 20268-K · 2.02Revenue $27M (+39% y/y); GAAP gross margin 29.6; Non-GAAP gross margin 29.9earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $27M | +39% y/y |
| GAAP gross margin · Q1-2026 | 29.6% | |
| Non-GAAP gross margin · Q1-2026 | 29.9% | |
| GAAP net loss · Q1-2026 | $-2M | |
| GAAP diluted EPS · Q1-2026 | $-0.03 | |
| Non-GAAP net loss · Q1-2026 | $-600000.00 | |
| Capital raise amount · Q1-2026 | $633M |
Risks flagged
STAR Market IPO for Tongmei remains subject to CSRC approval; lengthy and uncertain process.
“The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process.” · word for word
Company still reporting net losses, though narrowing significantly.
“GAAP net loss... was a net loss of $1.6 million”
Execution risk on large capacity expansion ($632.5M capital raise).
“completed a capital raise for $632.5 million in support of Tongmei’s indium phosphide capacity expansion” · word for word
21 Apr 20268-K · 1.01, 8.01AXT entered into an underwriting agreement for a public offering of 8,560,311 shares at $64.25 per share, expected gross proceeds ~$550M, with an option for additional shares up to ~$632.5M. Proceeds to fund capacity expansion for indium phopen
Figures in the filing · each found in the filing text
| Gross Proceeds (Base) · Q2-2026 | $550M | |
| Gross Proceeds (Full) · Q2-2026 | $633M | |
| Shares Offered (Base) · Q2-2026 | 8,560,311 | |
| Offering Price Per Share · Q2-2026 | $64.25 |
Risks flagged
Dilution from share issuance; lock-up agreements restrict insider sales for 60 days.
“8.56M shares offered; lock-up agreements for executive officers and directors.”
20 Apr 20268-K · 2.02AXT pre-announces Q1 2026 revenue $26-28M (below prior expectations) and net loss $1.6-2.6M, indicating a miss vs. consensus.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $28M | |
| Net loss attributed to Company · Q1-2026 | $-2M | |
| Net loss per share (basic and diluted) · Q1-2026 | $-0.03 |
Guidance
Q1 2026 revenue $26-28M; net loss $1.6-2.6M; EPS ($0.03)-($0.05)
Pre-announcement of Q1 2026 results below expectations, indicating demand weakness and margin pressure.
Risks flagged
Revenue guidance range suggests demand weakness in substrate market.
“Revenue range $26-28M, well below prior quarter or consensus.”
31 Mar 2026DEF 14AProxy statement filed for annual meeting, including proposals to increase authorized shares and advisory vote on executive compensation.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $88M | |
| Gross Profit · FY2025 | $11M | |
| Operating Expense · FY2025 | $33M | -14% y/y |
| Net Income (Loss) · FY2025 | $-21M | |
| Capital Expenditures · FY2025 | $6M | 0% y/y |
| Gross Proceeds from Secondary Offering · Q4-2025 | $100M |
Risks flagged
China Export Control Risk
“Established detailed procedures to comply with the February 4, 2025 export requirements implemented by China's Ministry of Commerce;” · word for word
Profitability Risk
“The 40% discretionary portion of the NEO bonus was reduced or eliminated because we were not profitable.” · word for word
Share Dilution Risk
“To approve an amendment to the Company’s Restated Certificate of Incorporation, as amended, to increase the total number of authorized shares of common stock, par value $0.001 per share, from 70,000,000 to 120,000,000” · word for word
17 Mar 202610-KAnnual report filed with generic risk factor language; no material event or specific operational signal.open
Risks flagged
Stock price volatility and potential delisting
“The bid price of our common stock has in the past closed below the $1.00 minimum per share bid price required for continued inclusion on The Nasdaq Global Select Market under Marketplace Rule 5450(a).” · word for word
Environmental regulation and factory shutdowns in China
“We expect that mandatory factory shutdowns may occur in the future. If the frequency of such shutdowns increases, especially at the end of a quarter, or if the total number of days of shutdowns prevents us from producing enough wafers to ship, then the shutdowns will have a material adverse effect on our manufacturing output, revenue and factory utilization.” · word for word
Litigation and securities class action
“we, along with our Chief Executive Officer, Morris Young, and our Chief Financial Officer, Gary Fischer, are the subject of a complaint alleging violations of federal securities laws.” · word for word
19 Feb 20268-K · 2.02Revenue $23M (-8% y/y); GAAP gross margin 20.9; Non-GAAP gross margin 21.5; Guidance: Sequential revenue growth expected in Q1 2026earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $23M | -8% y/y |
| GAAP gross margin · Q4-2025 | 20.9% | |
| Non-GAAP gross margin · Q4-2025 | 21.5% | |
| GAAP net loss · Q4-2025 | $4M | -31% y/y |
| Non-GAAP net loss · Q4-2025 | $2M | -47% y/y |
| Revenue (FY) · FY2025 | $88M | -11% y/y |
| GAAP gross margin (FY) · FY2025 | 12.7% | |
| Non-GAAP gross margin (FY) · FY2025 | 13.1% | |
| GAAP net loss (FY) · FY2025 | $21M | +84% y/y |
| Non-GAAP net loss (FY) · FY2025 | $18M | +312% y/y |
Guidance
Sequential revenue growth expected in Q1 2026
CEO expects sequential revenue growth in Q1 2026 driven by indium phosphide for AI, and plans to double capacity.
Risks flagged
Export permit delays impacting revenue and growth
“didn’t receive as many export permits in Q4 as we had hoped” · word for word
Significant gross margin compression in FY2025 (12.7% vs 24.0% in FY2024)
“GAAP gross margin for fiscal year 2025 was 12.7 percent of revenue, compared with 24.0 percent of revenue in fiscal year 2024.” · word for word
Widening net losses in FY2025
“GAAP net loss for fiscal 2025 was a net loss of $21.3 million, compared with a net loss of $11.6 million for fiscal 2024.” · word for word
9 Jan 20268-K · 2.02, 7.01Guidance: Revenue $22.5-23.5M vs prior expectationsearningsopen
Guidance
Revenue $22.5-23.5M vs prior expectations
Revenue guidance cut due to export permit delays, but demand remains very strong; company plans capacity expansion.
Risks flagged
Export control permit uncertainty from China
“Fewer export permits for indium phosphide issued by China's Ministry of Commerce than expected.”
30 Dec 20258-K · 1.01, 8.01Additional shares issued 1,064,773; Offering price per share $12.25; Additional gross proceeds $13Mopen
Figures in the filing · each found in the filing text
| Additional shares issued · Q4-2025 | 1,064,773 | |
| Offering price per share · Q4-2025 | $12.25 | |
| Additional gross proceeds · Q4-2025 | $13M |
Risks flagged
Equity dilution from additional share issuance may pressure EPS.
“1,064,773 additional shares issued at $12.25.”
13 Nov 202510-QAXT reported Q3 2025 results with gross margin improving to 22.3% but North American revenue collapsing to ~1% due to tariffs and export controls.earningsopen
Figures in the filing · each found in the filing text
| Gross Margin · Q3-2025 | 22.3% | |
| North America Revenue Share · North America · Q3-2025 | 1.0% | |
| Tariffs Paid · 9M-2025 | $271000.00 |
Risks flagged
Export control escalation
“On February 4, 2025, China added indium phosphide substrates to its export control list. As a result, the three wafer substrate product families manufactured by Tongmei all require permits from China’s Ministry of Commerce before they can be exported from China.” · word for word
Tariff escalation to 100%
“Tariffs on our products increased to 100%.” · word for word
Customer project cancellation
“we were informed by our customer that its end-user customer cancelled its project. While there may be other end users, this particular cancellation is the loss of a potentially high-volume sales opportunity.” · word for word
30 Oct 20258-K · 2.02Revenue $28M (+19% y/y); GAAP gross margin 22.3; Non-GAAP gross margin 22.4; Guidance: Revenue up 56% QoQ; InP revenue >250% sequential growth; gross margin expanded from 8.0% to 22.3%earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $28M | +19% y/y |
| GAAP gross margin · Q3-2025 | 22.3% | |
| Non-GAAP gross margin · Q3-2025 | 22.4% | |
| GAAP net loss · Q3-2025 | $-2M | +34% y/y |
| Non-GAAP net loss · Q3-2025 | $-1M | +43% y/y |
| Indium phosphide revenue growth · Indium Phosphide · Q3-2025 | 250.0% |
Guidance
Revenue up 56% QoQ; InP revenue >250% sequential growth; gross margin expanded from 8.0% to 22.3%
Strong Q3 results with revenue and margin recovery; management optimistic about 2026 growth and profitability driven by data center upgrade cycle.
Risks flagged
Dependence on China-based manufacturing and regulatory approvals for STAR Market IPO introduces geopolitical and execution risk.
“AXT has its Asia headquarters in Beijing, China and manufacturing facilities in three separate locations in China. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities.” · word for word
Export permits for indium phosphide orders were obtained; any future restrictions could impact revenue growth.
“We obtained export permits for a number of significant indium phosphide orders throughout the quarter.” · word for word
AXT, Inc. — questions
- What did AXT, Inc. file recently?
- 21 SEC filings in the last 12 months. Latest: 10-Q on 2026-08-13 — AXT reports continued impact from US tariffs and China export controls, with North America revenue dropping to 2% of total, and withdrawal of STAR Market IPO triggering $49M redemption rights.
Every figure on this page comes from AXT, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.